Park J - Search Results

1

Properties of Heparinoids Premixed with Tumor-Derived Extracellular Vesicles.

Manandhar S, Park J, Kothandan VK, Lee J, Alam F, Jee JP, Hwang J, Byun Y, Hwang SR. Manandhar S, et al. Among authors: park j. Bioconjug Chem. 2018 Nov 21;29(11):3757-3767. doi: 10.1021/acs.bioconjchem.8b00637. Epub 2018 Nov 5. Bioconjug Chem. 2018. PMID: 30372043

2

Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.

Kim JY, Shim G, Choi HW, Park J, Chung SW, Kim S, Kim K, Kwon IC, Kim CW, Kim SY, Yang VC, Oh YK, Byun Y. Kim JY, et al. Among authors: park j. Biomaterials. 2012 Jun;33(17):4424-30. doi: 10.1016/j.biomaterials.2012.02.066. Epub 2012 Mar 17. Biomaterials. 2012. PMID: 22425551

3

Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.

Chung SW, Lee M, Bae SM, Park J, Jeon OC, Lee HS, Choe H, Kim HS, Lee BS, Park RW, Kim SY, Byun Y. Chung SW, et al. Among authors: park rw, park j. Biomaterials. 2012 Dec;33(35):9070-9. doi: 10.1016/j.biomaterials.2012.09.002. Epub 2012 Sep 23. Biomaterials. 2012. PMID: 23010574

4

Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.

Adulnirath A, Chung SW, Park J, Hwang SR, Kim JY, Yang VC, Kim SY, Moon HT, Byun Y. Adulnirath A, et al. Among authors: park j. J Control Release. 2012 Nov 28;164(1):8-16. doi: 10.1016/j.jconrel.2012.10.001. Epub 2012 Oct 10. J Control Release. 2012. PMID: 23063549

5

Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.

Al-Hilal TA, Park J, Alam F, Chung SW, Park JW, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Al-Hilal TA, et al. Among authors: park jw, park j. J Control Release. 2014 Feb 10;175:17-24. doi: 10.1016/j.jconrel.2013.12.001. Epub 2013 Dec 12. J Control Release. 2014. PMID: 24333628

6

Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.

Alam F, Chung SW, Hwang SR, Kim JY, Park J, Moon HT, Byun Y. Alam F, et al. Among authors: park j. J Appl Toxicol. 2015 Jan;35(1):104-15. doi: 10.1002/jat.2995. Epub 2014 Feb 16. J Appl Toxicol. 2015. PMID: 24532548

7

Functional transformations of bile acid transporters induced by high-affinity macromolecules.

Al-Hilal TA, Chung SW, Alam F, Park J, Lee KE, Jeon H, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Al-Hilal TA, et al. Among authors: park j. Sci Rep. 2014 Feb 25;4:4163. doi: 10.1038/srep04163. Sci Rep. 2014. PMID: 24566561 Free PMC article.

8

Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice.

Kim JY, Alam F, Chung SW, Park J, Jeon OC, Kim SY, Son WC, Byun Y. Kim JY, et al. Among authors: park j. Anticancer Drugs. 2014 Oct;25(9):1061-71. doi: 10.1097/CAD.0000000000000141. Anticancer Drugs. 2014. PMID: 25003253

9

Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.

Alam F, Al-Hilal TA, Chung SW, Park J, Mahmud F, Seo D, Kim HS, Lee DS, Byun Y. Alam F, et al. Among authors: park j. J Control Release. 2015 Jan 10;197:180-9. doi: 10.1016/j.jconrel.2014.11.009. Epub 2014 Nov 15. J Control Release. 2015. PMID: 25445701

10

Size Controlled Heparin Fragment-Deoxycholic Acid Conjugate Showed Anticancer Property by Inhibiting VEGF165.

Park J, Jeong JH, Al-Hilal TA, Kim JY, Byun Y. Park J, et al. Bioconjug Chem. 2015 May 20;26(5):932-40. doi: 10.1021/acs.bioconjchem.5b00133. Epub 2015 May 5. Bioconjug Chem. 2015. PMID: 25894217

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68,292 results

Search Page